Trial Profile

A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2023 Results of subgroup analysis of data from the STEVIE study establishing a model to predict treatment outcome of periocular locally advanced basal cell carcinoma based on initial response to treatment with vismodegib, published in the Eye
12 Dec 2017 Results (n=6) of retrospective data from advanced BCC patients enrolled in this clinical trial who discontinued vismodegib due to PD and were then retreated with the same drug, were published in the Targeted Oncology.
23 Oct 2017 Results of primary analysis (n=1215, data cut-off :16 Mar 2015), published in the European Journal of Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com